A comprehensive international research initiative has illuminated significant variations in how individuals grappling with the persistent effects of COVID-19, commonly referred to as "long COVID," articulate their experiences, particularly concerning cognitive and emotional well-being. Findings from a large-scale comparative study indicate that patients in the United States report a markedly higher incidence of "brain fog" – a constellation of cognitive impairments characterized by difficulties with concentration, memory, and clear thinking – as well as pronounced psychological distress, including depression and anxiety, when contrasted with their counterparts in nations with lower per capita income, such as India and Nigeria. This divergence, researchers posit, is not attributable to inherent biological differences in the severity of the illness itself but rather to a complex interplay of sociocultural factors, including varying levels of healthcare access, established diagnostic pathways, and prevailing attitudes towards mental health and cognitive well-being. The implications of this research are far-reaching, suggesting that a substantial global population may be experiencing debilitating long COVID symptoms without adequate recognition or support.
The groundbreaking study, spearheaded by Northwestern Medicine, represents a pivotal first attempt to systematically compare the neurological sequelae of long COVID across diverse continental settings. The investigation meticulously followed the progress of over 3,100 adults diagnosed with long COVID, each of whom underwent evaluation at academic medical centers strategically located in Chicago, Illinois; Medellín, Colombia; Lagos, Nigeria; and Jaipur, India. A critical aspect of the study’s design was its focus on individuals who were largely not hospitalized during their initial SARS-CoV-2 infection, a segment of the population where persistent symptoms are often observed. Within this cohort, a striking 86% of American participants reported experiencing brain fog. In stark contrast, the prevalence of this symptom was reported by 63% of patients in Nigeria, 62% in Colombia, and a considerably lower 15% in India. This substantial differential underscores the varied landscape of symptom reporting and recognition across different global contexts.
A similar pattern of disparity was evident when examining mental health symptoms. Nearly three-quarters of non-hospitalized patients in the United States indicated experiencing depression or anxiety as a consequence of long COVID. This figure diminished to approximately 40% in Colombia, while fewer than one-fifth of patients in Nigeria and India reported comparable levels of psychological distress. These findings strongly suggest that cultural norms, societal attitudes towards mental health, and the availability of mental health services play a crucial role in how individuals perceive, articulate, and seek help for these debilitating conditions.
Dr. Igor Koralnik, the senior author of the study and the Chief of Neuro-infectious Disease and Global Neurology at Northwestern University’s Feinberg School of Medicine, offered critical insights into the observed discrepancies. He articulated that a cultural acceptance of discussing mental health and cognitive challenges is more prevalent in the United States and Colombia compared to Nigeria and India. In the latter regions, the study authors suggest that a combination of factors, including cultural denial of mood disorder symptoms, lingering stigma associated with mental health issues, misperceptions about neurological conditions, the influence of religiosity and deeply held belief systems, and a general deficit in health literacy, could contribute to a pattern of underreporting. Furthermore, the study highlights that a scarcity of mental health providers and a perceived lack of effective treatment options in these countries may exacerbate this issue, leading to a significant underestimation of the true burden of long COVID-related psychological and cognitive impairment.
Despite the notable variations in symptom reporting, the study did identify a core set of neurological symptoms that were consistently prevalent across all participating regions. These common manifestations of long COVID included brain fog, persistent fatigue, myalgia (muscle pain), headaches, dizziness, and various sensory disturbances such as numbness or tingling sensations. These findings provide a baseline understanding of the physiological challenges posed by the condition, irrespective of geographical location or socioeconomic context.
However, the prevalence of sleep disturbances, another significant symptom of long COVID, also displayed considerable variation. Close to 60% of non-hospitalized patients in the United States reported experiencing insomnia, a considerably higher proportion than the roughly one-third or fewer of patients in Colombia, Nigeria, and India who reported similar sleep difficulties. This further reinforces the notion that contextual factors significantly influence the reporting and potentially the experience of long COVID symptoms.
Statistical analysis of the symptom patterns revealed a clear demarcation between countries categorized as high- and upper-middle-income nations, such as the United States and Colombia, and those classified as lower-middle-income countries, like Nigeria and India. This division in symptom reporting and prevalence strongly correlates with differences in socioeconomic development, healthcare infrastructure, and cultural attitudes towards health and illness.
The observational study, conducted between 2020 and 2025, enrolled adult participants experiencing ongoing neurological symptoms following a confirmed COVID-19 infection. The recruitment strategy involved academic medical centers across the four distinct geographical locations, ensuring a diverse patient population that included both individuals who had been hospitalized and those who had not. To facilitate a robust comparative analysis, researchers employed standardized neurological, cognitive, and quality-of-life assessment tools that were uniformly applied at each participating site. This meticulous approach ensured that the data collected was comparable across the different regions, allowing for meaningful conclusions to be drawn regarding cross-continental variations.
Long COVID, a condition defined by the persistence of symptoms for weeks, months, or even years after the initial SARS-CoV-2 infection, continues to affect millions globally. Current estimates suggest that between 10% and 30% of adults who contract COVID-19 develop lingering health issues, with cognitive and neurological impairments being among the most debilitating and disruptive. The study’s authors underscore the profound societal impact of long COVID, noting that it disproportionately affects young and middle-aged adults during their most productive years, leading to significant detriments in workforce participation, overall productivity, and the capacity for innovation worldwide. In the context of this specific research, patients in the United States consistently reported the most substantial neurological and psychological burden, which, as Dr. Koralnik elaborated, significantly compromised their quality of life and their ability to engage in gainful employment. Dr. Koralnik, who also holds significant leadership roles at Northwestern Medicine and the Havey Institute for Global Health, emphasized that these findings are critical for understanding the global ramifications of the pandemic.
The implications of these findings are profound and underscore the urgent need for a more nuanced and culturally sensitive approach to the diagnosis and management of long COVID. The researchers advocate for the development and implementation of screening tools and diagnostic methodologies that are attuned to the specific cultural contexts and linguistic nuances of different populations. Moreover, the study highlights the critical necessity of robust healthcare systems capable of providing sustained, long-term care and follow-up for individuals affected by long COVID. Building upon this foundational research, Dr. Koralnik and his international collaborators are actively engaged in testing cognitive rehabilitation treatments specifically designed for long COVID brain fog. These innovative therapeutic studies are currently underway in Colombia and Nigeria, employing identical treatment protocols that were originally developed and refined for patients at the Shirley Ryan AbilityLab in Chicago. This collaborative effort signifies a commitment to translating research findings into actionable interventions that can address the unmet needs of long COVID patients worldwide. The study’s formal title is "A cross-continental comparative analysis of the neurological manifestations of Long COVID."
About the Author
